Human vascular endothelial growth factor 121 gene-modified materials repair firearm-induced radial defects

doi:10.3969/j.issn.2095-4344.2015.47.004

Abstract

Abstract:

BACKGROUND: Bone defects are the leading cause of nonunion after firearm injury. Firearm injury is relatively special. Autograft and allograft all have big drawbacks, which cannot meet the requirements of basic-level hospitals. Using tissue-engineered bone with good blood vessels and osteogenic capability in repair of firearm bone defect will be an ideal and feasible restoration method.

OBJECTIVE: To explore the application of human vascular endothelial growth factor 121 gene-modified materials in the repair of firearm-induced radial injury in rabbits.

METHODS: A total of 128 rabbits were randomly divided into surgical injury group and firearm injury group (n=64 per group). In the firearm injury group, 0.25 g steel ball was launched using 56-style musket to establish a firearm radial injury model; in the surgical injury group, surgical methods were used to produce a 1.2 cm radial injury model. Human vascular endothelial growth factor 121 gene-modified materials were used. The related histocytes from rabbits were harvested to obtain bone marrow stromal cells for culture. A porous scaffold material was prepared. The obtained materials were respectively implanted into radial defect sites in the surgical injury and firearm injury groups. The application of human vascular endothelial growth factor 121 gene-modified materials in rabbit radial defect repair was analyzed.

RESULTS AND CONCLUSION: Compared with the surgical injury group, at 8, 12 and 16 weeks after repair, the gray level ratio of bone defect site and the anti-compression mechanical ratio at the healthy and repairing sides of the radius in the firearm injury group were decreased (P < 0.05), and the new bone area increased (P < 0.05). At 2 and 4 weeks after repair, the local blood flow at the repair area was significantly increased (P < 0.05). These results suggest that compared with the surgical injury group, the curative effect of human vascular endothelial growth factor 121 gene is more ideal in the firearm injury group because of the emergence of local ischemia and hypoxia in the process of radial defect repair. Human vascular endothelial growth factor 121-modified material can repair bone marrow stromal cells. The application of human vascular endothelial growth factor 121 in firearm burns can enhance the synthesis and secretion of angiogenic factors, improve the local blood flow, reduce anti-compression mechanical ratio, and increase the new bone area.
中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Tissue Engineering, Biocompatible Materials, Bone Transplantation

Wang Jian-zhong, Li Bing-cang, Ren Bao, Gao Fei, Li Cong-jie, Liu Wei, Wang Xiao-dong, Lei Ming, Gao Wen-shan. Human vascular endothelial growth factor 121 gene-modified materials repair firearm-induced radial defects[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(47): 7561-7566.

Figures/Tables 3

References

[1] 刘岩,马信龙.人工骨修复材料及金属钛材料在骨组织工程中的应用[J].中国组织工程研究,2012,16(12):2229-2232.

[2] 马育林,戴如春,盛志峰,等.骨细胞密度对骨生物力学性能的影响[J].中华老年医学杂志,2009,28(6):500-504.

[3] 辛雷,苏佳灿.人工骨修复材料的现状与展望[J].创伤外科杂志, 2011, 13(3):272-284.

[4] 宋雪莲,于静涛,刘扬,等.壳聚糖在骨组织工程中应用研究进展[J].中国实用口腔科杂志,2013,6(5):306-310.

[5] 孟志斌,李德豪,周健强,等.可吸收珊瑚羟基磷灰石与天然珊瑚修复骨缺损的组织学及影像学分析[J].生物骨科材料与临床研究, 2007,4(5):10-15.

[6] 侯喜君,王春华,李霖,等.β-磷酸三钙煅烧骨修复兔股骨远端骨缺损[J].中国组织工程研究,2013,17(3):400-406.

[7] 杨华清,张明宇,党晓谦,等.复合同种异体成骨细胞的β-磷酸三钙人工骨修复桡骨缺损[J].中国组织工程研究,2013,17(34): 6061-6066.

[8] 张文志,王潇,段丽群,等.纳米羟基磷灰石/聚酰胺66复合人工椎体在颈椎病前路椎体次全切除术中的临床应用[J].中国骨与关节损伤杂志,2012,27(9):783-785.

[9] Swetha M, Sahithi K, Moorthi A, et al. Synthesis, characterization, and antimicrobial activity of nano-hydroxyapatite-zinc for bone tissue engineering applications. J Nanosci Nanotechnol. 2012;12(1):167-172.

[10] Shen L, Yang H, Ying J, et al. Preparation and mechanical properties of carbon fiber reinforced hydroxyapatite/ polylactide biocomposites. J Mater Sci Mater Med. 2009; 20(11): 2259-2265.

[11] 姚旺祥,马安,朱六龙,等.浓缩自体骨髓复合纤维蛋白胶修复兔桡骨陈旧性骨缺损[J].中国医学科学院学报,2011,33(4): 387-392.

[12] 肖裕华,李绍琴,潘文峰,等.纤维蛋白胶复合骨形态发生蛋白与VEGF修复兔桡骨缺损的实验研究[J].实用临床医学,2013,14(6): 17-19.

[13] Pei M, He F, Boyce BM, et al. Repair of full-thickness femoral condyle cartilage defects using allogeneic synovial cell-engineered tissue constructs. Osteoarthritis Cartilage. 2009;17(6):714-722.

[14] 佟刚,雷静,钟翠红,等.不同PH与蛋白含量的胶原海绵植入缺损骨组织部位的疗效及安全性考察[J].生物医学工程学杂志,2012, 29(6):1125-1130.

[15] 杨春蓉,王迎军,陈晓峰.纳米羟基磷灰石/胶原/磷酸丝氨酸仿生复合骨组织工程支架材料的制备及表征[J].中国科学杂志,2013, 58(3):267-271.

[16] 李娟,郑闱颖,卢岩,等.骨形成蛋白-2基因修饰的β磷酸三钙/胶原复合材料修复颅骨缺损[J].材料科学与工程学报,2013,31(2): 248-252.

[17] Ramay HR, Zhang M. Biphasic calcium phosphate nanocomposite porous scaffolds for load-bearing bone tissue engineering. Biomaterials. 2004;25(21):5171-5180.

[18] Maquet V, Boccaccini AR, Pravata L, et al.Porous poly (a-hydroxyacid)/ Bioglasss composite scaffolds for bone tissue engineering. I: preparation and in vitro characterization. Biomaterials. 2004;25(18):4185-4194.

[19] Niemeyer P, Szalay K, Luginbuhl R, et al. Transplantation of human mesenchymal stem cells in a non-autogenous setting for bone regeneration in a rabbit critical-size defect model. Acta Biomater. 2010;6(3):900-908.

[20] Liu Y, Pei G, Jiang S. New porous beta-tricalcium phosphate as a scaffold for bone tissue engineering. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008;12(23):4563-4567.

[21] 彭吾训,王蕾,邓进,等.一种组织工程骨修复兔股骨头坏死模型的效果评价[J].第三军医大学学报,2010,32(7):661-664.

[22] 赵玫,吴海珍,王鑫,等.牙源性双相陶瓷的研制及其骨缺损修复实验[J].安徽医科大学学报,2013,48(6):617-620.

[23] 姚彪,钱卫庆,尹宏,等.新型α-半水硫酸钙/双相生物陶瓷人工骨修复兔桡骨骨缺损的X射线评估[J].中国组织工程研究,2014, 18(47): 7550-7555.

[24] inheiro AL, Santos NR, Oliveira PC, et al. The efficacy of the use of IR laser phototherapy associated to biphasic ceramic graft and guided bone regeneration on surgical fractures treated with wire osteosynthesis: a comparative laser fluorescence and Raman spectral study on rabbits. Lasers Med Sci. 2013;28(3):815-822.

[25] Wu CC, Yang KC, Yang SH, et al. In vitro studies of composite bone filler based on poly(propylene fumarate) and biphasic α-tricalcium phosphate/hydroxyapatite ceramic powder. Artif Organs. 2012;36(4):418-428.

[26] Froum SJ, Wallace SS, Cho SC, et al. Histomorphometric comparison of a biphasic bone ceramic to anorganic bovine bone for sinus augmentation: 6- to 8-month postsurgical assessment of vital bone formation: a pilot study. Int J Periodontics Restorative Dent. 2008;28(3):273-281.

[27] Pinheiro AL, Aciole GT, Ramos TA, et al. The efficacy of the use of IR laser phototherapy associated to biphasic ceramic graft and guided bone regeneration on surgical fractures treated with miniplates: a histological and histomorphometric study on rabbits. Lasers Med Sci. 2014; 29(1):279-288.

[28] 刘瑞丽,吴学建,王利民,等.多孔双相陶瓷复合重组人骨形态发生蛋白-2和碱性成纤维细胞生长因子缓释微球的异位成骨活性[J].中华实验外科杂志,2011,28(7):1045-1047.

[29] 周献伟,孙勇.纳米磷酸钙陶瓷人工骨治疗跟骨骨缺损的X射线评价[J].中国医师杂志,2011,13(5):676-677.

[30] 王蕾,彭吾训,张爱华,等.双相陶瓷生物骨-骨形态发生蛋白-碱性成纤维细胞生长因子复合物修复股骨头坏死模型的实验研究[J].中国康复理论与实践,2013,19(5):426-431.

[31] 王丽丽.复合性生物活性陶瓷在颌骨囊肿骨缺损修复中的应用[J].黑龙江医药,2012,25(1):128.

[32] 郑磊,王前,魏宽海,等.碱性成纤维细胞生长因子对成骨细胞粘附特性影响的实验研究. 中国修复重建外科杂志,2000,14(5):305-307.

[33] 陈亚军,叶古祥,孙国娣.MTT法体外测定胃癌化疗药物敏感性[J].中国普通外科杂志,2003,12(1):47-49.

[34] Hu BL, Joshua MN, Dong CY, et al. Development of a novel recombinant adenovirus containing gfp–zeocin fusion expression cassette for conditional replication in p53-deficient human tumor cells. J Viroll Meth. 2004;117(2):129-136.

[35] Allipour Birgani S, Mailänder M, et al. Efficient therapy of ischaemic lesions with VEGF₁₂₁-fibrin in an animal model of systemic sclerosis. Ann Rheum Dis. 2015.

[36] Ciomber A, Smagur A, Mitrus I, et al. Antitumor effects of recombinant antivascular protein ABRaA-VEGF₁₂₁ combined with IL-12 gene therapy. Arch Immunol Ther Exp (Warsz). 2014;62(2):161-168.

[37] Zhang Y, Hong H, Niu G, et al. Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF₁₂₁. Mol Pharm. 2012;9(12):3586-3594.

[38] Rosengart TK, Bishawi MM, Halbreiner MS, et al. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF₁₂₁ cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther. 2013;24(2):203-208.

[39] Mohamedali KA, Niu G, Luster TA, et al. Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. Biochem Pharmacol. 2012;84(11):1534-1540.

[40] Smirnikhina SA, Lavrov AV, Bochkov NP. Dynamics of elimination of plasmids and expression of VEGF121 gene transfected into human mesenchymal stem cells by different methods. Bull Exp Biol Med. 2011;151(1):121-125.

[41] Cho EJ, Yang J, Mohamedali KA, et al. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF₁₂₁/rGel. Invest Radiol. 2011;46(7):441-449.

[42] Mohamedali KA, Li ZG, Starbuck MW, et al. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res. 2011;17(8):2328-2338.

[43] Woods AK, Hoffmann DS, Weydert CJ, et al. Adenoviral delivery of VEGF₁₂₁ early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension. 2011;57(1):94-102.

[44] Xu D, Fuster MM, Lawrence R, et al. Heparan sulfate regulates VEGF165- and VEGF₁₂₁-mediated vascular hyperpermeability. J Biol Chem. 2011;286(1):737-745.

[45] Cai C, Böttcher MC, Werner JA, et al. Differential expression of VEGF₁₂₁, VEGF₁₆₅ and VEGF₁₈₉ in angiomas and squamous cell carcinoma cell lines of the head and neck. Anticancer Res. 2010;30(3):805-810.

[46] Smagur A, Boyko MM, Biront NV, et al. Chimeric protein ABRaA-VEGF₁₂₁ is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth. Acta Biochim Pol. 2009;56(1):115-1124.

[47] Kawai H, Minamiya Y, Ito M, et al. VEGF₁₂₁ promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer. 2008;59(1):41-47.

[48] Clere N, Bermont L, Fauconnet S, et al. The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF₁₂₁) transcription from the promoter through a p53-independent mechanism. Exp Cell Res. 2007;313(15):3239-3250.

[49] Pan Q, Chathery Y, Wu Y, et al. Neuropilin-1 binds to VEGF₁₂₁ and regulates endothelial cell migration and sprouting. J Biol Chem. 2007;282(33):24049-24056.

[50] Liu LS, Wei DH, Tang CK, et al. A HUVEC line with a stable expression of the VEGF₁₂₁ gene to achieve complete endothelialization of blood conduits. Artif Cells Blood Substit Immobil Biotechnol. 2007;35(3):319-331.

[51] von Wronski MA, Tweedle MF, et al. Binding of the C-terminal amino acids of VEGF₁₂₁ directly with neuropilin-1 should be considered. FASEB J. 2007;21(7):1292-1293.

[52] Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF₁₂₁/rGel. J Nucl Med. 2007;48(3):445-454.

[53] Catena R, Muniz-Medina V, Moralejo B, et al. Increased expression of VEGF₁₂₁/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int J Cancer. 2007;120(10):2096-2109.

[54] Kim S, Mohamedali KA, Cheung LH, et al. Overexpression of biologically active VEGF₁₂₁ fusion proteins in Escherichia coli. J Biotechnol. 2007;128(3):638-647.

[55] 张元平,崔继秀,裴国献,等.植入神经的自体骨髓基质细胞-β磷酸三钙复合体修复兔长骨骨缺损[J].中国组织工程研究与临床康复,2006,10(13):62-66.